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A B S T R A C T
Objectives: To compare the use of pair-wise meta-analysis methods to multiple treatment
comparison (MTC) methods for evidence-based health-care evaluation to estimate the effec-
tiveness and cost-effectiveness of alternative health-care interventions based on the available
evidence.
Methods: Pair-wisemeta-analysis andmore complex evidence syntheses, incorporating an
MTC component, are applied to three examples: 1) clinical effectiveness of interventions for
preventing strokes in people with atrial fibrillation; 2) clinical and cost-effectiveness of
using drug-eluting stents in percutaneous coronary intervention in patients with coronary
artery disease; and 3) clinical and cost-effectiveness of using neuraminidase inhibitors in
the treatment of influenza. We compare the two synthesis approaches with respect to the
assumptions made, empirical estimates produced, and conclusions drawn.
Results: The difference between point estimates of effectiveness produced by the pair-wise
and MTC approaches was generally unpredictable—sometimes agreeing closely whereas in
other instances differing considerably. In all three examples, the MTC approach allowed the
inclusionof randomizedcontrolledtrialevidence ignoredinthepair-wisemeta-analysisapproach.
This generally increased the precision of the effectiveness estimates from theMTCmodel.
Conclusions: The MTC approach to synthesis allows the evidence base on clinical effec-
tiveness to be treated as a coherent whole, include more data, and sometimes relax the
assumptions made in the pair-wise approaches. However, MTC models are necessarily
more complex than those developed for pair-wise meta-analysis and thus could be seen as
less transparent. Therefore, it is important that model details and the assumptions made
are carefully reported alongside the results.
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A core component of evidence-based health-care evaluations is
to estimate the effectiveness and cost-effectiveness of alterna-
tive health-care interventions based on the available evidence.
Ideally, effectiveness data are obtained from well-conducted
randomized controlled trials (RCTs). Where multiple relevant
RCTs exist, appropriate evidence synthesis methods should be
used. For comparisons between two specific interventions it is
common practice to use pair-wise meta-analysis methods [1] to
obtain a pooled estimate of effectiveness that may be used to
inform the associated economic analyses. Nevertheless, there
may be interest in comparingmore than two competing health-
care interventions to answer policy-relevant questions, or the
interventionsof interestmayhavebeen trialledagainst different
andmultiple comparators. In the former case, it is unlikely that
RCTs exist that compare all the interventions of interest directly.
Multiple treatment comparisons (MTCs) [2–5] have been pro-
posed that allow the simultaneous estimation of the compara-
tive effectiveness ofmultiple treatments using an evidence base
of trials that individually do not compare all treatment options.
Suchmethods are a logical extension tomore establishedmeta-
analysis methods. Currently there is much deliberation regard-
ing the use of MTC methods for health technology assessment
(HTA) with the UK National Institute for Health and Clinical Ex-
cellence (NICE) (whichprovidesguidance for EnglandandWales)
now advising they can be used, but not as the base case in their
Methods Guide [6]. Similar institutions in Australia and Canada
are also cautious about their use [7,8].
In light of this current controversy, the aim of this article is
to assess the added value of MTCmethods by comparing their
use with standard pair-wise meta-analysis models when esti-
mating pooled estimates of effectiveness and to inform deci-
sion modelling. Three case studies are considered: 1) use of
aspirin to prevent stroke in individuals with atrial fibrillation.
This case study considers issues surrounding the expansion of
the evidence network used with respect to estimates of effec-
tiveness obtained; 2) use of drug-eluting stents in percutane-
ous coronary intervention (PCI) in patients with coronary ar-
tery disease. This example considers the impact of using an
MTC, allowing for estimates at multiple time points, on an
economic decision model; and 3) use of neuraminidase inhib-
itors in the treatment of influenza. In this case study, infor-
mation of censoring is incorporated into a simple evidence
network to informa decisionmodel. Before these case studies,
a brief overview of MTC methods is presented.
Overview of MTC Methods
MTCs extend the more established meta-analysis methods to
allow the comparison of three or more interventions [2–4].
The main assumptions of an MTC analysis are that [9]:
● The trials to be synthesised form a connected network (Ex-
amples of diagrammatic representations of trial networks
are given in Figures 1, 3, and 6). In each of these, there are
no treatments that are isolated and not compared to atleast one of the other treatments in the network (i.e., all the
treatment nodes are connected by lines indicating that a
randomized comparison exists leaving no isolated nodes
without a connection).
● There is a consistency across the evidence base. Consider a
three-treatment network with treatments labelled A, B,
andC. Themethod assumes that, if two-arm trials compar-
ing B versus C exist, then if such trials had a third, A, arm,
then they would produce an estimate of A versus C and A
versus B that was consistent (i.e., assumes the underlying
effects to be identical or sampled from the same distribu-
tion depending whether fixed or random effects are as-
sumed in the synthesis model) with any A versus C and A
versus B trials that may actually exist. A further feature of
MTC is that networks can be extended to include RCTs for
which only one, or even none, of the treatments relevant to
the decision question of interest are evaluated. Although
such evidence may not initially seem relevant to the deci-
sion of interest (and may require a non-traditional search
strategy to identify [10]), they can reduce uncertainty in the
comparisons of interest (as well as providing an opportu-
nity for assessing the consistency of the evidence). There-
fore, when MTC methods are used, issues relating to the
structure and scope of the network require careful consid-
eration. Network scope will be discussed in the case stud-
ies that follow.
Many of the methods for implementing MTC have been de-
veloped using the Markov chain Monte Carlo (MCMC)WinBUGS
software [11]. However, in their simplest formMTCmethods can
be viewed as a type of regression model [2–4] and therefore are
possible, but challenging, to fit using classical statistical meth-
ods. Within an MCMC framework it is fairly straightforward to
extend the standard MTC model to incorporate more complex
data structures (such asmultiple time points and censored time
to event data). Aswewill show, this potentially allowsmoredata
tobe included in thesynthesiswhile relaxingassumptionsmade
in standard pair-wise meta-analysis.
Case Studies
In this section, both pair-wise meta-analysis and more com-
plex evidence syntheses, incorporating an MTC component,
are applied to three examples and compared with respect to
the 1) assumptions the models make; 2) empirical estimates
produced; and 3) conclusions drawn. ExtendedMTCmethods,
which account for outcomes reported at multiple time points
[12] (i.e., to ensure correlation between effect size outcomes
assessed at different time points on the same individuals is
maintained) and allowing for censored data [13], are pre-
sented in cases studies 2 and 3. These two case studies also
consider cost-effectiveness by inputting the effectiveness es-
timates obtained from the alternative synthesis approaches
into decisionmodels originally developed as part of treatment
appraisals commissioned by the National Institute of Health
and Clinical Excellence in the UK.
Where multiple estimates of effectiveness are required for
the decision model (e.g., estimates for different treatments
373V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 7 1 – 3 8 0Fig. 1 – Network diagrams of stroke prevention treatments for individuals with non-rheumatic atrial fibrillation. Each
treatment strategy is a node in the network. The links between the nodes are trials or pairs of trial arms. The numbers
along the link lines indicate the number of trials or pairs of trial arms for that link in the network.
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374 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 7 1 – 3 8 0and/or time points) then it is important to maintain the cor-
relation structure between these estimates when inputting
them into the decisionmodel. One approach is to evaluate the
decision model within the same modelling framework as the
synthesis by fitting all the analysis within a single coherent
MCMC framework [14] ensuring any correlations between pa-
ameters are automatically respected (used in case study 2).
lternatively the parameter estimates from each MCMC sim-
lation could be used to inform a decision model evaluated
singMonte Carlo simulation (e.g., Excel, Microsoft Corp, Red-
ond, WA) retaining their correlation structure throughout
used in case study 3).
All of the MTC models are evaluated within an MCMC
ramework using the WinBUGS software [11] where all prior
istributions specified are intended to be non-informative.
Use of aspirin to prevent stroke in individuals with atrial
fibrillation
There have been a number of evidence syntheses conducted
to estimate the effect of different interventions for the pre-
vention of stroke in individuals with atrial fibrillation [15–
22]. All of these reviews, except one [21], have used standard
pair-wise meta-analyses to obtain pooled estimates of ef-
fectiveness. Cooper et al. [21] used a random effect MTC to
estimate effectiveness. The network diagram from this
analysis, displaying the interventions that have been con-
sidered in RCTs together with the number of times each
intervention has been compared to another intervention, is
presented in Figure 1C.
Using the evidence base associated with the network com-
piled by Cooper et al., we now explore the implications of
using three different approaches to the estimation of effec-
tiveness for the single comparison of aspirin versus pla-
cebo: 1) pair-wise random effects meta-analysis of aspirin
versus placebo (M-A); 2) random effects MTC of all trials, in-
cluding aspirin and/or placebo arms (MTC aspirin or placebo
RCTs); and 3) random effects MTC of all trials of anticoagulant
and antiplatelet therapies (MTC all RCTs).
Currently the standard approach in HTA for investigating
the clinical effectiveness of aspirin compared to placebo (M-A
model) would be to search and identify the (four) RCTs that
directly address this question (Fig. 1A).
However, how would the estimate and its associated un-
certainty change if a broader evidence base were used and
MTC methods utilized? To investigate this we now consider
extending the evidence base to the RCTs in atrial fibrillation
that include arms randomizing to either of the two treatments
of interest; that is, placebo or aspirin (MTC Aspirin or Placebo
RCTs model). This extends the network to include 18 further
randomized comparisons, which are derived from 12 further
RCTs (Fig. 1B) (i.e., some trials included more than two arms
andhencemademultiple comparisons although this informa-
tion is not represented on the Fig. 1B) introducing a further
four treatment nodes. Notice that some of these new compar-
isons form alternative indirect “routes” for comparing placebo
to aspirin (i.e., indirect routes via warfarin, alternate-day as-
pirin, and low-dose warfarin and aspirin all now exist) thusproviding further information about the comparison of inter-
est and reducing uncertainty.
Finally, we extend the network to all RCTs of anticoagulant
and antiplatelet therapies that were available when the orig-
inal analysis was published, by including RCTs that did not
consider either placebo or aspirin therapy (MTC all RCTs
model). This adds in a further 10 comparisons from six RCTs
and introduces a further two treatment nodes (Fig. 1C). This
further increases the indirect “routes” that connect placebo to
aspirin.
The results from these three different analyses, all im-
plemented using the WinBUGS software, are displayed in
Figure 2.
It can be observed that incorporating more data into the
analysis through the MTC models greatly reduced the uncer-
tainty changing a non-statistically significant result obtained
from the pair-wise meta-analysis (pooled relative risk [RR]
0.744; 95% credible interval [CrI] 0.406–1.576, between-study
variance [2] 0.091; 95% CrI 0.000–2.311) into a statistically sig-
nificant one (RR 0.648; 95%CrI 0.457–0.877 and 2 0.027; 95%CrI
0.000–0.276, and RR 0.633; 95% CrI 0.441–0.885 and 2 0.044;
95% CrI 0.000–0.298 for MTC aspirin or placebo RCTs and MTC
all RCTs models, respectively). It can also been observed that
the uncertainty in the pooled rate ratio is increased slightly for
MTC all RCTsmodel compared toMTC aspirin or placebo RCTs
model despite the inclusion of more information. This is due
to the increase in the between-study variance (which mea-
sures thewithin-treatment comparison between-study heter-
ogeneity) that in turn reduces the absolute weight given to
each study in the synthesis.
This example clearly illustrates that use of MTC methods
can have an influence on estimates of effectiveness (both
point estimate and uncertainty around it). The inclusion of
more evidence will generally reduce the uncertainty of an es-
timate. Concern has been raised regarding whether such esti-
mates are reliable (i.e., unbiased), and this depends on
whether the assumptions of themodel hold (as outlined in the
previous section). An initial assessment of the goodness of fit
of the model predictions to the observed data for each of the
models using the posterior mean residual deviance (D ) sug-
gested that all models fitted the data well (i.e., under the null
Fig. 2 – Pooled results obtained from three different
analyses: pair-wise meta-analysis (M-A) of aspirin versus
placebo, multiple treatment comparison (MTC) of all
randomized controlled trials (RCTs) including aspirin or
placebo arm or both, and MTC of all RCTs. CrI, credible
interval.hypothesis that the model provides an adequate fit to the
bd
t
l
f
a
m
t
(
375V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 7 1 – 3 8 0data, it is expected that D is approximately equal to the num-
er of unconstrained data points (pair-wiseM-AD  7.32 com-
pared to eight unconstrained data points, MTC (aspirin or pla-
cebo RCTs) 30.02 compared to 33 unconstrained data points,
and MTC (all RCTs) 45.31 compared to 45 unconstrained data
points).
We have focused on the results of one comparison here. Of
course, one of the advantages ofMTC is that it can compare all
treatments in a connected network simultaneously, and even
obtain probabilities that each treatment is ‘best’ (i.e., most
cost-effective). Case studies 2 and 3 consider decision prob-
lems with more than two alternatives. Clearly situations such
as the one considered above, in which the effectiveness pa-
rameter changes considerably with synthesis model, could
have important implications for any decisionmodel, and sub-
sequent policy decisions, which are sensitive to such param-
eters. We consider the impact on the results of the synthesis
on the results of economic decision models in case studies 2
and 3.
Use of drug-eluting stents in PCI in patients with coronary
artery disease
In 2007 a UK National Health Service HTA was published that
assessed the effectiveness and cost-effectiveness of using
drug-eluting stents in PCI in patients with coronary artery dis-
ease [23]. Pair-wisemeta-analyses were carried out in the sys-
tematic review component of the report for different drug-
eluting stent designs compared to bare-metal stents, for a
range of outcomes (e.g., mortality, myocardial infarction
events, revascularisation), and time points. However, the eco-
nomic evaluation only considered bare-metal stents versus
drug-eluting stents regardless of the type and the outcome of
target lesion revascularisation at 1 year assuming the esti-
mated effect is stable beyond the first year and all other out-
comes to be equal. Themodel was evaluated deterministically
(i.e., uncertainty was not taken into account).
Since the HTA report in 2007, Stettler et al. [24] published a
MTCof outcomes associatedwith drug-eluting stents (Cypher,
Cordis, Bridgewater, NJ and Taxus, Boston Scientific, Natick,
MA) and bare-metal stents. To incorporate data from the
range of follow-up times reported by the different studies si-
multaneously, their analysis used a randomwalkmodel based
on piece-wise constant hazards [12]. This model assumed es-
timates of effectiveness to be more similar at adjacent time
points than estimates at far-off time points. This hierarchical
(random effects) model also allows heterogeneous variance
between studies so that the two types of drug eluting stents
(Cypher and Taxus) can be assumed to bemore similar to each
other than to bare metal stents. Figure 3 shows the network
iagram for this MTC analysis but note that the numbers on
he diagramonly relate to the number of trials reporting target
esion revascularisation at 1 year (i.e., the time point required
or the economic decision model), as this number will vary
cross time points.
Here we consider the following three evidence synthesis
odels to estimate the pooled relative risk or hazard ratio for
arget lesion revascularisation in a subgroup of individuals
i.e., those experiencing an elective procedure, with a narrowdefinition of target lesion revascularisation, as given by Hill et
al. [23]) with Cypher or Taxus drug-eluting stents versus bare-
metal stents: 1) pair-wise random effects meta-analysis of
Taxus or Cypher versus bare-metal stents using data at 1 year
(M-A); 2) random effects MTC of Taxus versus Cypher versus
bare-metal stents using data at 1 year (MTC); and 3) hierarchi-
cal random effects MTC using data from multiple time points
(1, 2, 3, and 4 years) of Taxus versus Cypher versus bare-metal
stents (MTC multiple time points) [24].
All of the above analyses included the appropriate trial
data used in the Stettler et al. analysis [24] and were carried
out in the WinBUGS software. Note that the M-A and MTC
were carried out on the relative risk scale but the MTC multi-
ple time points model was carried out on the hazard ratio
scale; therefore, care should be taken when directly compar-
ing and interpreting the results.
The pooled relative risk/hazard ratio for target lesion re-
vascularisation in individualswith Cypher or Taxus drug-elut-
ing stents versus bare-metal stents from the three different
evidence syntheses are presented in Figure 4.
This shows the point estimates of Cypher andTaxus versus
baremetal stents to be very similar for theM-A andMTCmod-
els but shows a slight increase for the MTC multiple time
pointsmodel. The uncertainty is reduced in theMTC andMTC
multiple time points models compared to M-A model (de-
picted by the narrower confidence/credible intervals).
The M-A and MTC models fitted the data well (i.e., M-A
Taxus vs. bare-metalD  19.47 compared to 18 unconstrained
data points, M-A Cypher vs. bare-metal 32.80 compared to 34
unconstrained data points, and MTC 70.85 compared to 71
unconstrained data points), but the MTCmultiple time points
model fitted less well (i.e., D  181.3 compared to 162 uncon-
strained data points). This latter finding concurswith the orig-
inal analysis by Stettler et al. [24] for the outcome target lesion
revascularisation.
Pooled estimates are then input as distributions into the
Fig. 3 – Network diagram of stents used in percutaneous
coronary intervention in patients with coronary artery
disease. Each treatment strategy is a node in the network.
The links between the nodes are trials or pairs of trial
arms. The numbers along the link lines indicate the
number of trials or pairs of trial arms for that link in the
network with target lesion revascularisation data at 1 year.economic decision model, developed as part of the 2007 HTA
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models, if any, on the overall cost-effectiveness result. Un-
like the 2007 HTA model, many of the parameters in the
decisionmodel were expressed as distributions to represent
the uncertainty in their estimation. A list of the distribu-
tions assigned to each parameter is given in the Appendix
found at: doi:10.1016/j.jval.2010.09.001.
Figure 5 shows the cost-effectiveness acceptability curves
or the M-A, MTC, and MTC multiple time points models. The
lot shows the probability that Cypher and Taxus are cost-
ffective compared to baremetal stents for a range of values a
ecision-maker may be willing to pay per additional quality-
djusted life years (QALYs). In this particular example, as the
mount a decisionmaker is willing to pay per additional QALY
ncreases the probability that drug-eluting stents are cost-ef-
ective compared to bare metal stents also increases.
Fig. 4 – Pooled relative risks/hazard ratios for target lesion re
obtained from the three different analyses (meta-analysis [M
points).
Fig. 5 – Cost-effectiveness acceptability curves for the stents
effectiveness acceptability curves of Cypher vs. Taxus vs. ba
being presented in terms of difference in costs and effects b
not on the actual costs and effects. M-A, meta-analysis. MTC, muUse of neuraminidase inhibitors in the treatment of
influenza
The third case study revisits a recentHTA conducted to inform
UK National Institute for Health and Clinical Excellence guid-
ance on the effectiveness and cost-effectiveness of using
neuraminidase inhibitors (NIs) (antiviral drugs) for the treat-
ment of influenza [25]. This assessment was an update to pre-
vious guidance published in 2003 [26]. Both HTAs considered
two NIs: zanamivir and oseltamivir. The evidence base con-
sidered in both appraisals was relatively straightforward. A
number of RCTs existed comparing the effectiveness of zana-
mivir or oseltamivir versus placebo but there were no head-
to-head trials comparing the two NIs directly, nor were there
any trials of the NIs versus any other active comparator.
Therefore, the network structure was relatively straightfor-
cularisation at 1 year with 95% credible interval (CrI)
multiple trial comparison [MTC], and MTC multiple time
mple. Note that it was not possible to plot cost-
etal stents due to the original cost-effectiveness analysis
en the two drug-eluting stents and bare metal stents andvas
-A],exa
re m
etweltiple trial comparison. QALY, quality-adjusted life years.
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zanamivir and oseltamivir (Fig. 6).
Here we consider the different evidence synthesis ap-
proaches to estimate the effectiveness parameters for use in
the economic decision model (i.e., mean difference in time to
the alleviation of symptoms and return to normal activities)
adopted by the two HTAs:
1. pair-wise random effect meta-analysis of zanamivir or
oseltamivir versus placebo assuming time to event curves
follow an exponential distribution (M-A) [26]; and
. randomeffectsMTCof zanamivir versus oseltamivir versus
placebo assuming time to event curves follow a Weibull
distribution (hierarchical MTC) [25].
or comparison, the M-A model was updated to incorporate
he same data as used in the MTC model (i.e., to include the
ore recently published RCTs).
Due to a proportion of individuals still with symptoms at
he end of the RCTs, the challenge for both appraisals was
ow to deal with this censoring of the data. This was par-
icularly problematic as the outcomes of interest for the
ecision model (that is, mean time to symptoms alleviated
nd mean time to return to normal activities) are undefined
here censoringwas present (clinically, the focus had been on
he difference inmedian times and thiswas estimable fromall
rials because censoring was always on less than 50% of pa-
ients). To estimate the mean durations (and associated stan-
ard errors) in each of the arms of the RCTs in the presence of
he censoring, the 2003 appraisal assumed that the survival
urves for times to alleviation of symptoms/return to normal
ctivities followed an exponential distribution [27]. Separate
air-wise meta-analysis models were fitted for each of the
hree patient groups of interest—otherwise healthy adults,
therwise healthy children and at-risk individuals (i.e., indi-
iduals of any age with a concurrent disease severe enough to
equire regular medical follow-up or hospital care (e.g.,
hronic disorders such as chronic respiratory disease, cardio-
ascular disease, and pulmonary disorders) plus otherwise
ealthy elderly individuals aged 65 years and older). For com-
Fig. 6 – Network diagram of antiviral drugs for the
treatment of influenza assessment. Each treatment
strategy is a node in the network. The links between nodes
are trials or pairs of trial arms. The numbers along the
links indicate the number of trials or pairs of trial arms for
that link in the network for the outcome “time to
symptoms alleviated” and patient population “otherwise
healthy.”arison to the 2009 appraisal results, an estimate for the indi-rect comparison of zanamivir versus oseltamivir has been cal-
culated classically using the methodology outlined by Bucher
et al. [28].
The 2009 appraisal adopted a more sophisticated evidence
synthesis model (further details, including the WinBUGS
model available elsewhere [25]) originally developed and fitted
to the 2003 appraisal dataset as part of further research [13].
This analysis relaxes the assumption that the survival curves
are exponential in shape and instead fits a more flexible (i.e.,
two parameter) Weibull distribution to the survival curves for
both outcomes using themedian data. In doing so, it takes into
account further data that was available on the numbers still ill
at the end of the reported follow-up since this informs a sec-
ond point on the time to alleviation of symptoms/return to
normal activities survival curve. The analysis models both
outcomes simultaneously so information can be borrowed
across outcomes for RCTs that do not report both outcomes.
The three specific patient subgroups defined earlier plus a
mixed population (the latter was used to include patients in
trials where it was not possible to obtain stratified results for
the subgroups of interest) were considered distinctly in the
economic evaluation. These were also simultaneously mod-
elled assuming exchangeability across each of the treatment/
subgroup combinations that allow a borrowing of strength
that increases the precision of the subgroup-specific esti-
mates. Although this model automatically provides indirect
comparison estimates for zanamivir versus oseltamivir, given
the simple evidence structure, such an estimate could be ob-
tained classically using standard indirect comparison meth-
odology [28], and thus this is not the main advantage of the
sophisticated modelling. Rather, it is in the other modelling
complexities outlined above and facilitated within the net-
work framework, which sets this analysis apart from the fre-
quentist approach.
Figure 7 reports the estimates of treatment effect for
each NI versus placebo and for the two NIs head to head for
time to alleviation of symptoms and time to return to nor-
mal activities.
Across all the outcomes, except one, the NIs are esti-
mated to be associated with a larger treatment difference
compared to placebo in the hierarchical MTC model com-
pared to the M-A model. The uncertainty is usually greater
in the Bayesian analysis also reflected in the wider (and
often asymmetric) credible intervals. The uncertainty was
also generally greater in the head-to-head comparisons
from the Bayesian synthesis model although the difference
between the point estimates from the two models was less
predictable. In summary, while unpredictable, the differ-
ences between the two analyses are quite considerable for a
proportion of the estimates. Both M-A and hierarchical MTC
models fit the data well; that is, the posterior mean residual
deviance, D , is approximately equal to the number of un-
constrained data points. However, when the hierarchical
MTC model was fitted assuming an exponential (as as-
sumed in the M-A model) rather than Weibull distribution
the fit of the model was poor (i.e., D  405.5 compared to 139
unconstrained data points).
Figure 8 presents the acceptability curves for an at-risk
adult population resulting from a decision model using the
378 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 7 1 – 3 8 0hierarchical MTC model and the simple M-A model for effec-
tiveness inputs. It can be seen that for a willingness to pay of
£5000 per QALY gained or above, zanamivir would appear to
be the most cost-effective intervention for this subgroup re-
gardless of approach used to estimate effectiveness, although
the hierarchical MTC model increases the difference between
the two NI treatments by approximately 20% (after £5,000 per
QALY gained). Clearly, these sorts of differences could impact
Fig. 7 – Evidence synthesis results for the influenza example
(MTC) by population. CrI, credible interval.
Fig. 8 – Cost-effectiveness acceptability curves for at-risk ad
years.onmodel conclusions in situationswhere acceptability curves
for different treatments are closer together.
Discussion
In this article we have attempted to compare three state-of-
the-art Bayesian synthesis models with more standard (pair-
ng pair-wise meta-analysis and multiple trial comparison
n the influenza example. QALY, quality-adjusted lifeusiults i
379V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 7 1 – 3 8 0wise) meta-analytic approaches for estimation of clinical ef-
fectiveness. Since the latter two case studies consider MTC
models with further modelling refinements, these compari-
sons are not “pure” MTC versus pair-wise synthesis but com-
plex evidence synthesis versus pair-wise meta-analysis.
Important findings that these case studies highlight in-
clude: 1) MTC methods allow the inclusion of evidence that is
ignored in pair-wise modelling, and this inclusion of further
evidence generally reduces the uncertainty in effectiveness
parameters; 2) imposing hierarchical structures on data (e.g.,
to allow for multiple time points) can also decrease uncer-
tainty through the inclusion of extra evidence; 3) relaxing
strong assumptions in the pair-wise modelling facilitated by
theMCMC framework (e.g., in case study 3, to include a second
time-point to estimate a survival curve, the curve was as-
sumed to followaWeibull rather than exponential shape)may
appropriately increase uncertainty; and 4) bothMTC and hier-
archical aspects of the synthesis modelling can change point
estimates, and it is difficult to anticipate by howmuch and in
which direction before carrying out the evidence synthesis
and thus the impact on the results of the cost-effectiveness
models.
A common, but unworkably vague, phrase in guidance for
decision models is that “all relevant evidence” should be used
to inform (effectiveness) model parameters [6]. We believe
this article highlights just how difficult it is to produce awork-
able definition of relevant evidence, but one would clearly
need to address issues relating to trial networks (i.e., as shown
in case study 1), and time points (i.e., case studies 2 and 3).
Both of these issues relate to evidence that may influence the
effectiveness parameters of interest, although it may not be
immediately obvious that such evidence is “relevant.” Fur-
ther, this article has only considered randomised evidence,
although it is acknowledged that observational evidence, or
even expert opinion, may sometimes be considered “rele-
vant”; for example, in situations where there is no or limited
trial evidence, orwhere the trial evidencemaynot relate to the
patient populations being considered in the decision model-
ling.We are currently exploring further case studies wherewe
compare the results of using trial data only with results ob-
tained by using trial data augmented with observational data
and expert opinion to further explore these issues.
It is important to note that the case studies cannot demon-
strate onemethod is superior to the other with respect to bias
and precision of parameter estimates since no gold standard
approach exists and thus there is no way of knowing what the
truth is. What we can say is that themore complex approaches
consider the evidence as a coherent whole, include more data,
and sometimes relax the assumptions made in the pair-wise
approaches (although imposing hierarchical structures on the
MTC network can also make stronger assumptions by assum-
ing subgroups/regression parameters are exchangeable
across treatments). Against this is the acknowledgement that
the more complex models can be very nonintuitive to under-
stand and time-consuming to undertake. It is possible to
check the goodness-of-fit of the model predictions to the ob-
served data, and it is important to do this for all synthesis
models regardless of complexity (i.e., including standard pair-
wise meta-analysis).The authors thank Professor Adrian Bagust for providing
the necessary information that allowed us to replicate the
original decision model for case study 2, and Louise Long-
worth, PhD, and conference delegates for their interesting and
useful discussion of a previous version of this work presented
at Health Economists’ Study Group meeting in Sheffield, UK,
July 2009.
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